CEL-SCI Corp. | |
Stock Exchange | NYSE |
EPS |
$1.27 |
Market Cap |
$283.78 M |
Shares Outstanding |
33.7 M |
Public Float |
27.95 M |
Address |
8229 Boone Boulevard Vienna Virginia 22182 United States |
Employees | - |
Website | http://www.cel-sci.com |
Updated | 07/08/2019 |
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. |